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0939-4753/ª 2015 Elsevier B.V. All rights reseAbstract Background and aims: We have reported that adverse effects on ﬂow-mediated dila-
tion of an acute elevation of non-esteriﬁed fatty acids rich in saturated fat (SFA) are reversed
following addition of long-chain (LC) n-3 polyunsaturated fatty acids (PUFA), and hypothesised
that these effects may be mediated through alterations in insulin signalling pathways. In a sub-
group, we explored the effects of raised NEFA enriched with SFA, with or without LC n-3 PUFA, on
whole body insulin sensitivity (SI) and responsiveness of the endothelium to insulin infusion.
Methods and results: Thirty adults (mean age 27.8 y, BMI 23.2 kg/m2) consumed oral fat loads on
separate occasions with continuous heparin infusion to elevate NEFA between 60 and 390 min.
For the ﬁnal 150 min, a hyperinsulinaemic-euglycaemic clamp was performed, whilst FMD and
circulating markers of endothelial function were measured at baseline, pre-clamp (240 min) and
post-clamp (390 min). NEFA elevation during the SFA-rich drinks was associated with impaired
FMD (P Z 0.027) whilst SFA þ LC n-3 PUFA improved FMD at 240 min (P Z 0.003). In males,
insulin infusion attenuated the increase in FMD with SFA þ LC n-3 PUFA (P Z 0.049), with SI
10% greater with SFA þ LC n-3 PUFA than SFA (P Z 0.041).
Conclusion: This study provides evidence that NEFA composition during acute elevation inﬂu-
ences both FMD and SI, with some indication of a difference by gender. However our ﬁndings
are not consistent with the hypothesis that the effects of fatty acids on endothelial function
and SI operate through a common pathway.
This trial was registered at clinical trials.gov as NCT01351324 on 6th May 2011.
ª 2015 Elsevier B.V. All rights reserved.t; eNOS, endothelial nitric
ME, fatty acid methyl ester;
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rved.Introduction
Non-esteriﬁed fatty acids (NEFA) have been proposed to
be a mediator of insulin signalling defects in both skeletal
muscle and endothelial tissue [1,2]. Elevation of NEFA in
healthy subjects by co-infusing Intralipid (a commercial
lipid preparation) and heparin has been reported to impair
glucose uptake and the phosphoinositide 3 kinase (P13K)
signalling pathway in skeletal muscle [3e5], as well as
reduce endothelial function. This pathway in endothelial
cells regulates vascular tone via activation of endothelial
Table 1 Formulation of the test drinks.
SFA SFA þ LC n-3 PUFA
Palm stearin (g/kg bw)a 0.75 0.65
Fish oil concentrate (g/kg bw)a e 0.1
Composition of oils (%)
Palmitic acid; 16:0 59 51
Stearic acid; 18:0 5 4
Oleic acid; 18:1 n-9 28 24
Linoleic acid; 18:2 n-6 6 5
Arachidonic acid; 20:4 n-6 e 0.3
Eicosapentaenoic acid; 20:5 n-3 e 1.2
Docosapentaenoic acid; 22:5 n-3 e 0.4
Docosapentaenoic acid; 22:5 n-6 e 0.7
Docosahexaenoic acid; 22:6 n-3 e 10.4
a A 70 kg individual would receive 53 g palm stearin or 46 g palm
stearin þ7 g ﬁsh oil concentrate.
576 K.J. Newens et al.nitric oxide synthase (eNOS) with production of the
vasodilator, nitric oxide (NO). Lind et al. reversed the
NEFA-induced impairment of forearm blood ﬂow in
response to methacholine [5] by infusion of insulin, sup-
porting the notion that elevated NEFA impair endothelial
function via induction of insulin resistance in this tissue.
Dietary fat quality may be a contributory factor in both
impaired insulin sensitivity [6] and endothelial function
[7]. In vitro studies report more adverse effects of satu-
rated (SFA) than unsaturated fatty acids on the endothelial
PI3K insulin signalling pathway and NO production
[8e10]. In human studies, the impact of SFA is less clear,
however, chronic supplementation with the long chain n-3
polyunsaturated fatty acids (LC n-3 PUFA) found in ﬁsh oil
has been consistently shown to improve endothelial
function in a variety of populations [11e13]. We have
previously reported that adverse effects of acute elevation
of NEFA rich in SFA on ﬂow-mediated dilatation (FMD) are
reversed following addition of LC n-3 PUFA [14]. Here
using an experimental protocol, we test the hypothesis
that SFA and LC n-3 PUFA differentially affect both whole
body insulin sensitivity (SI) and the responsiveness of the
endothelium to insulin infusion. For this study, we chose
to focus on the eNOS Glu298 subgroup only, thereby
excluding subjects carrying the less common allele, and
providing a more homogeneous and representative pop-




From a larger cohort genotyped for a common poly-
morphism in the eNOS gene (rs1799983, Glu298Asp) [15],
ﬁfteen males and ﬁfteen females homozygous for Glu298
were matched for age (mean  SD, 27.8  11.9 y) and BMI
(23.2  3.0 kg/m2). All subjects were healthy non-smokers
who were not taking greater than 1 g eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) per day, or any
medication known to inﬂuence blood clotting, lipids or
blood pressure. The subjects were screened for fasting
cholesterol (mean  SD 4.62  0.76 mmol/L), triglyceride
(TG) (1.06  0.28 mmol/L) and glucose (5.15  0.64 mmol/
L). Subjects were recruited between March 2009 and
January 2010.
Study design
This was a single-blind crossover study; subjects attended
the Hugh Sinclair Unit of Human Nutrition on two occa-
sions separated by four weeks for females (to control for
possible effects of the menstrual cycle on FMD) or at least
one week for males. Subjects were randomly assigned to
one of the fat loads on each day using an online number
generator. Investigators responsible for performing and
analysing the FMD and insulin clamp measures were
blinded to the allocation and were not involved in the
preparation or serving of the fat loads.Protocol
The study protocol has been described elsewhere [14].
Brieﬂy, on each study day participants arrived fasted and
following a baseline FMD measurement, a cannula was
inserted at the wrist for venous blood sampling. A bolus fat
load (66 g) was consumed at 0 min, followed by smaller
volumes (22 g) every 30 min for a further 390 min. At
60 min, a second cannula was inserted into the antecubital
vein in the sampling arm for the infusion of heparin. A
bolus of heparin (500 IU) was followed by a continuous
infusion (0.4 IU/kg body weight/min) for the remainder of
the study day. At 240 min, a 150 min hyperinsulinaemic-
euglycaemic clamp was performed; both insulin and
glucose were co-infused into the same cannula as the
heparin. Measurements of FMD were also performed
immediately prior to (240 min) and at the end (390 min) of
the insulin clamp.
The procedures followed in the current study were in
accordance with the ethical standards of the University of
Reading Research and Ethics Committee. Written informed
consent was obtained from all subjects.Test drinks
Oral fat loads were prepared according to bodyweight
(Table 1) using palm stearin (AarhusKarlshman Ltd, UK)
with or without the addition of DHA-rich ﬁsh oil (Croda
Healthcare, UK), 30 g skimmed milk powder (Premier In-
ternational Foods Ltd, UK), 15 g chocolate powder (The
Spanish Chocolate Co Ltd, UK) and 0.5 g monoglyceride
emulsiﬁer (Danisco, Denmark). Water was added to ach-
ieve a ﬁnal weight of 352 g. The SFA and SFA þ LC n-3 PUFA
test drinks were identical in protein (11.2 g) and carbo-
hydrate (27.1 g) content.FMD
FMD of the brachial artery was measured by trained re-
searchers using an ATL Ultrasound HDI5000 broadband
ultrasound system (ATL Ultrasound, Bothell, Washington)
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described [16]. Brieﬂy, following baseline imaging, a blood
pressure cuff was inﬂated to 220 mm Hg to occlude blood
ﬂow for 5 min. Analysis of the images was performed using
wall-tracking software (MIA-llc). FMD response was calcu-
lated using change from baseline to peak diameter divided
by baseline and reported as a percentage value.
Hyperinsulinaemic-euglycaemic clamp
Venous blood glucose was sampled immediately prior to
the commencement of the hyperinsulinaemic-
euglycaemic clamp at 240 min [17] to provide the target
concentration for the duration of the clamp, before insulin
(Actrapid, Novo Nordisk, Copenhagen, Denmark) was
infused at 100 mU/kg body weight (bw) for the duration of
the 150 min clamp. At 2 min, 20% (w/v) dextrose infusion
was initiated, the rate of which being determined by blood
glucose which was analysed at 5 min intervals (HemoCue
Glucose 201þ, HemoCue AB, Ängelholm, Sweden). The
steady state glucose infusion rate over the ﬁnal 30 min of
the clamp provided an index of whole body SI and was
expressed as mg $ min1 $ kg1 of fat-free mass (FFM).
FFM was measured using a bioimpedance device (BC
418 MA, Tanita Europe, Amsterdam, The Netherlands).
Biochemical measures
Venous blood samples were collected every 30 min into K3
EDTA (for NEFA, ET-1, insulin and C-peptide) or serum
tubes (TG, NOx). To limit in vitro lipolysis, the EDTA sam-
ples were placed immediately on ice and processed within
30 min [18]. For analysis of C-peptide, 500 KIU of apo-
protinin (Fisher Scientiﬁc, Loughborough, UK) was added
per ml plasma to protect against proteolysis. NEFA and TG
were quantiﬁed using an ILAB 600 (Instrumentation lab-
oratory, Warrington, UK) with kits by Alpha Laboratories
(Eastleigh, UK) and Instrumentation Laboratory respec-
tively. ET-1 was measured by ELISA (R&D systems Europe
Ltd, Abingdon, UK) and NOx using a NO quantiﬁcation kit
(Actif Motif, Rixensart, Belgium).
Plasma C-peptide and insulin were quantiﬁed using a
multiplex assay system (Luminex 100, Invitrogen, Paisley,
UK) with a Milliplex Endocrine Panel (Millipore Corp,
Watford, UK). NEFA composition analysis was performed by
extracting lipids from 800 ml of plasma collected at baseline
(the two baseline samples were pooled) and 240 min [14].
Statistical analysis
At 95% power and 5% signiﬁcance, the minimum number
of subjects required to detect a difference of 1.5% in FMD
response between the two oral fat loads was calculated to
be 22. Additional subjects were recruited (nZ 30) to allow
for possible dropouts.
SPSS version 17.0 (SPSS Inc., Chicago) was used for all
statistical analyses. Summary measures calculated for the
time-course data included area under the curve (AUC) and
incremental AUC (iAUC). Data were tested for normality; itwas necessary to log transform NEFA and TG values and
use non-parametric tests for the fatty acid composition of
NEFA. Independent and paired t-tests (or non-parametric
equivalent) were used to compare baseline and summary
measures between genders and fat loads, respectively. For
postprandial time-course data, repeated measures ANOVA
were performed using a mixed model approach. Bonfer-
roni correction was applied to control for multiple pair
wise comparisons. P  0.05 was considered signiﬁcant.Results
The fat loads were well tolerated by the subjects. Initial
analysis of the results revealed some differences by
gender; therefore data are also presented separately for
males and females where appropriate.
Insulin sensitivity and markers of insulin metabolism
There were no differences in fasting values or metabolic
responses as measured by iAUC for insulin, C-peptide, or
C-peptide: insulin ratio (a marker of insulin clearance) by
fat load or gender (Table 2). Males had a 10% higher SI
during the SFA þ LC n-3 PUFA compared to SFA regime
(PZ 0.041) whereas SI was similar in females between the
two fat loads (P Z 0.420).
Endothelial function
FMD response and circulating markers of endothelial
function are shown in Table 3. There was no signiﬁcant
difference in velocity, ﬂow, or shear rate between fat loads
at baseline or at the end of the study period (data not
shown). At baseline, males had a signiﬁcantly lower FMD
response than females (29%, P Z 0.03).
Impact of NEFA elevation (0e240 min) on FMD response
and circulating markers of endothelial function
For the group as a whole, compared with baseline, the SFA
load resulted in an impairment (P Z 0.027) whilst
SFA þ LC n-3 PUFA improved (P Z 0.003) the FMD
response at 240 min. The mean absolute difference in
change from baseline between the two fat loads was
1.35  0.22% (P < 0.001). There were some indications of
differential effects by gender for the change in FMD
following the fat loads (Table 3); the beneﬁcial effect of
SFA þ LC n-3 PUFA was signiﬁcant in females (P Z 0.004)
but not males (P Z 0.179); conversely the impairment of
FMD associated with the SFA load was evident in males
(P Z 0.017) but not in females (P Z 0.387). Serum NOx
declined to a similar extent during both fat loads
(P < 0.001) and did not differ by gender. Plasma ET-1 did
not change during either fat load in males or females.
Impact of insulin infusion on FMD and circulating
markers of endothelial function (240 mine390 min)
In males, insulin infusion signiﬁcantly reduced the post fat
load FMD value by 0.89  0.41% (P Z 0$049) during the
Table 2 Insulin sensitivity and measures of insulin metabolism.
Whole group Males Females
SFA SFA þ LC n-3 PUFA SFA SFA þ LC n-3 PUFA SFA SFA þ LC n-3 PUFA
SI (mg $ min1 $ kg1 FFM) 8.33  0.50 8.58  0.42 8.51  0.53 9.41  0.56* 8.16  0.86 7.74  0.47
Insulin
Fasting (pM) 89.5  10.3 79.7  8.6 92.7  16.7 78.7  13.5 86.4  12.8 80.6  11.5
iAUC (mM/L  240 min) 7.61  1.06 8.21  1.63 6.86  1.43 7.55  2.70 8.35  1.59 8.87  1.93
C-peptide
Fasting (pM) 503  36.5 476  37.8 463  43.2 419  37.1 542  58.5 532  63.4
iAUC (mM/L  240 min) 38.0  5.7 31.3  6.1 34.8  7.0 32.7  8.2 41.2  9.1 29.8  9.4
C-peptide: insulin ratio
Fasting 7.1  0.9 7.7  1.1 6.6  1.5 7.1  1.3 7.7  1.2 8.4  1.9
iAUC 207  119 393  181 243  222 239  195 172  100 546  309
Data are presented as mean  SEM; SI, insulin sensitivity. A signiﬁcant difference from SFA is notated by * (P < 0.05). Outcome measures were
available for a minimum of twelve males and twelve females.
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observed between 0 and 240 min was also reversed
following insulin infusion in males only (Fig. 1b); this was
only statistically signiﬁcant during SFA (P Z 0.017). For
females, there was no effect of insulin infusion on FMD or
NOx for either fat load (Fig. 1a and b). For females only,
insulin infusion was associated with a decrease in plasma
ET-1 (Fig. 1c), with statistical signiﬁcance only reached
during SFA (P Z 0.044); no effect was seen in males.
In the group as a whole, there were no signiﬁcant dif-
ferences in FMD or circulating markers of endothelial func-
tion after the insulin infusion (390 min) for either fat load.Serum NEFA and plasma TG
Baseline NEFA and TG did not differ by fat load or gender.
The oral fat-heparin protocol resulted in a two-fold
elevation of serum NEFA at 240 min as compared to
baseline (Fig. 2a). Concentrations of NEFA declined steadily
following initiation of the insulin infusion (240 min),
almost returning to baseline values at 390 min, with a
signiﬁcant effect of time only. NEFA response as measured
by iAUC0e390min was 70% greater in males than females
(110.3  14.2 mmol/L  390 min vs. 64.6  11.3 mmol/
L  390 min), P Z 0.015.Table 3 Measures of endothelial function from baseline to 240 min.
Whole group Males
SFA SFA þ LC n-3 PUFA SFA
FMD (%)
Baseline 5.36  0.48 5.23  0.46 4.35  0.5
D 240 min 0.62  0.27y 0.73  0.23*y 0.86  0.3
NOx (mM)
Baseline 24.0  1.4 23.3  1.1 24.3  2.3
D 240 min 3.8  0.7y 3.1  0.9y 4.6  1.0
ET-1 (ng/ml)
Baseline 1.07  0.09 1.04  0.09 1.15  0.1
D 240 min 0.07  0.08 0.06  0.07 0.05  0.1
Data are presented as mean  SEM. FMD; ﬂow-mediated dilatation; NOx
denoted by * whilst a signiﬁcant difference in the measures of endothel
measures were available for a minimum of fourteen males and fourteen fThe TG response remained within a narrow range
(Fig. 2b) but was signiﬁcantly higher during the SFA than
SFA þ LC n-3 PUFA regime (P Z 0.016). TG iAUC0e390min
revealed a greater reduction in TG over the study day in
males (64.4  14.3 mmol/L  390 min) than females
(20.5  13.2 mmol/L  390 min) (P Z 0.029), with no
difference by fat load.
Plasma NEFA composition
There was a signiﬁcant increase in the percentage weight
of SFA in the NEFA fraction of plasma from baseline (me-
dian 38.8%, IQ range 36.5e40.1%) to 240 min during both
fat loads (SFA; 46.0% (44.8e49.1); SFA þ LC n-3 PUFA;
43.7% (42.0e45.9); both P < 0$001). A signiﬁcant increase
in the proportion of LC n-3 PUFA during the SFA þ LC n-3
PUFA load (from 1.3% (1.0e1.8) to 6.8% (5.8e7.2)) was
observed at 240 min, consistent with a three-fold increase
in EPA and a ﬁve and a half-fold increase in DHA (all
P < 0.001).
Discussion
We have previously shown acute ingestion of SFA with LC
n-3 PUFA to reverse impairment in FMD observed with SFAFemales
SFA þ LC n-3 PUFA SFA SFA þ LC n-3 PUFA
0 4.44  0.43 6.37  0.74 6.01  0.76
1y 0.51  0.36* 0.39  0.43 0.94  0.27*y
22.2  1.4 23.7  1.4 24.3  1.6
y 2.4  0.9y 3.0  0.8y 3.9  1.6y
4 1.15  0.12 0.99  0.12 0.92  0.12
0 0.02  0.08 0.09  0.12 0.11  0.11
, total nitrites; ET-1, endothelin-1. A signiﬁcant difference from SFA is
ial function from baseline is notated by y (both P < 0.05). Outcome
emales.
Figure 1 Change in a) FMD, b) Serum NOx and c) Plasma ET-1 after insulin infusion (240 mine390 min) in females (n  13) and males (n  13)
following consumption of SFA (white bars) and SFA þ LC n-3 PUFA (grey bars). Data are presented as mean  SEM. There was no difference in any
measure between fat loads, signiﬁcant differences within a gender group is denoted by y (P < 0.05).
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indicate that the fatty acid composition of elevated NEFA is
an important factor inﬂuencing both endothelial function
and insulin sensitivity. There was also some evidence of
gender effects, suggesting that males were more respon-
sive to both the negative effects of SFA on FMD response,
and the positive effects of LC n-3 PUFA on insulin sensi-
tivity. Conversely, there were indications that females
were more responsive to the beneﬁcial effects of LC n-3Figure 2 Plasma a) NEFA and b) TG following consumption of SFA ( )
or SFA þ LC n-3 PUFA ( ), solid lines represent the females (nZ 15) and
broken lines the males (n Z 14). Data are presented as mean  SEM.
For both analytes, there was a signiﬁcant effect of time (P < 0.001).PUFA on FMD. Differences in lipid metabolism during the
protocol were also observed, with males having signiﬁ-
cantly higher NEFA concentrations than females.
Contrary to our hypothesis of a positive effect of in-
sulin infusion on endothelial function, attenuation of the
FMD response following exposure to NEFA rich in SFA did
not improve after insulin infusion in the group as a whole,
or in either gender. For the SFA þ LC n-3 PUFA fat load the
effects observed were complex as in males, insulin infu-
sion following this fat load was actually associated with a
decrease in FMD response. As FMD has been shown to be
dependent on NO bioavailability [19], it was expected
these various changes in FMD responses would be
mirrored by changes in circulating NOx but this was not
the case in our study. Unlike the FMD response, elevated
NEFA led to a reduction in circulating NOx after both fat
loads, with insulin attenuating this reduction in males,
but not in females. We interpret these complex ﬁndings
as indicating that in the presence of elevated NEFA
enriched in LC n-3 PUFA, a reduction in circulating NOx
does not result in a decrease in FMD. However, the lack of
association between these two measures may be attrib-
uted to the plasma NOx measurement which represents
not only NO production but also its degradation and
excretion. We propose that LC n-3 PUFA enhance endo-
thelial function through a number of mechanisms, some
of which may be independent of NO production and/or
insulin signalling. For example, in vitro studies show that
cytochrome P450 epoxygenases (CYP450) present in
endothelial cells can metabolise LC n-3 PUFA such as DHA
to fatty epoxides, which promote vasodilation through
activation of calcium-activated potassium channels pre-
sent in smooth muscle cells [20]. Of interest to the pre-
sent analysis, CYP450 enzymes have been shown to be
transcriptionally upregulated by oestrogen [21]. Whether
hormone dependent enhancement of CYP450 plays a role
in the more marked effect of LC n-3 PUFA on FMD
observed in females in this study remains to be deter-
mined but is worthy of further investigation given the
almost two fold greater response we have seen in our
female subjects.
580 K.J. Newens et al.Whilst experimental elevation of NEFA has been
consistently shown to impair whole-body insulin sensi-
tivity [3,22e24], there are very few studies which have
examined the impact of NEFA composition. Decreasing the
ratio of saturated: polyunsaturated fatty acids in a lipid
infusion with heparin signiﬁcantly improved insulin
sensitivity in healthy subjects [25], whereas no difference
was found in insulin sensitivity between infusions of
Intralipid with and without LC n-3 PUFA in subjects with
type II diabetes [26]. In the current study, only males had a
higher insulin sensitivity following SFA þ LC n-3 PUFA than
SFA alone.
The sampling of venous rather than arterial or arter-
ialised blood during the insulin clamp is a limitation of this
study. With the current protocol, it was not possible to
measure the primary outcome measure FMD whilst heat-
ing the hand as this has been shown to induce changes in
systemic vasodilation [27]. The use of venous blood sam-
pling is therefore a compromise but several studies do
support the use of venous blood for this purpose [27,28]. A
trend for a slight decline in conduit vessel endothelial-
independent vasodilatation has been previously reported
during physiological hyperinsulinaemia attributed to in-
sulin induced noradrenergic activation [29]. Due to the
intensive nature of our protocol, we did not determine the
dilatation of the brachial artery to glyceryl trinitrate prior
to or during the insulin clamp, which could be regarded as
a potential limitation of our study.
In conclusion, our study provides evidence for differ-
ential effects of SFA and LC n-3 PUFA on FMD and on SI
during acute NEFA elevation, with some indication of a
difference in response by gender. We had postulated that
the effects of elevated NEFA composition on impairment of
FMD might reﬂect the differential effects of dietary fatty
acids on the PI3K/Akt pathway that have been reported
from in vitro studies [8e10]. Whilst our observations are
not consistent with this hypothesis, explanation of our
ﬁndings have led us to suggest novel mechanisms by
which LC n-3 PUFA may improve endothelial function and
to speculate on differences in insulin dependent endo-
thelial pathways in males and females. The clinical and
public health relevance of the beneﬁcial effects we have
observed of LC n-3 PUFA on FMD and SI are potentially
signiﬁcant and need to be substantiated by clariﬁcation of
the underlying mechanisms involved.
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